Prime Medicine (PRME) Non-Current Deferred Tax Liability (2021 - 2024)

Prime Medicine has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $134000.0 in Q1 2024.

• For the quarter ending Q1 2024, Non-Current Deferred Tax Liability rose 74.03% year-over-year to $134000.0; the trailing twelve-month figure through Mar 2024 stood at $134000.0 (up 74.03% YoY), and the FY2022 full-year result was $8.7 million, up 46.57% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2024 stood at $134000.0, up from $108000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $8.7 million in Q4 2022, with the low at $77000.0 in Q1 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $2.6 million across 4 years, with a median of $307500.0 in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 46.57% — and 2024, when it surged 74.03%.
• Prime Medicine's Non-Current Deferred Tax Liability stood at $6.0 million in 2021, then surged by 46.57% to $8.7 million in 2022, then plunged by 98.77% to $108000.0 in 2023, then grew by 24.07% to $134000.0 in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $134000.0 (Q1 2024), $108000.0 (Q2 2023), and $77000.0 (Q1 2023), per Business Quant data.